肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：Taselisib联合Fulvestrant治疗晚期乳腺癌

2018-09-19 MedSci MedSci原创

晚期乳腺癌Taselisibfulvestrant
关注

CLIN CANCER RES近期发表了一篇文章，报道了Taselisib联合Fulvestrant治疗局部晚期或转移性HER2阴性，激素受体阳性绝经后乳腺癌患者的Ⅱ期临床试验结果。

CLIN CANCER RES近期发表了一篇文章，报道了Taselisib联合Fulvestrant治疗局部晚期或转移性HER2阴性，激素受体阳性绝经后乳腺癌患者的Ⅱ期临床试验结果。

患者口服Taselisib 6mg每天联合肌内注射Fulvestrant（500mg）直至出现疾病进展或不可耐受毒性。分析肿瘤组织PIK3CA突变情况。使用NCICTCAE v4.0记录不良反应。使用RECIST v1.1评估肿瘤反应。研究结果表明，中位治疗持续时间为4.6个月。所有患者均出现≥1级不良反应，30例患者出现≥3级不良反应，19例患者出现35种严重不良反应。47例患者的肿瘤组织可以进行PIK3CA突变评估（20例存在突变，27例未检测到突变）。PIK3CA突变患者最佳确认缓解率为38.5%，临床获益率为38.5%。PIK3CA-MND患者最佳确认缓解率为14.3%，临床获益率为23.8%，PIK3CA突变状态未知的患者最佳确认缓解率为20.0%，临床获益率为30.0%。

文章最后认为，Taselisib联合Fulvestrant治疗HER2阴性，激素受体阳性局部晚期或转移性乳腺癌患者具有临床活性，且与PIK3CA突变状态无关。未发现新的安全问题，目前正在进行Ⅲ期临床试验。

原始出处：
Maura N.Dickler,Cristina Saura,et al.Phase ⅡStudy of Taselisib(GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative,Hormone Receptor-Positive Advanced Breast Cancer.CLIN CANCER RES.September 2018 doi:10.11558/1078-0432.CCR-18-0613

本文系williamhill asia 医学（MedSci）原创编译整理，转载需授权！

评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2051244, encodeId=ec6220512440e, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Nov 02 05:46:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657071, encodeId=9b08165e07192, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri May 31 18:46:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2065860, encodeId=fd1e2065860e0, content=<a href='/topic/show?id=8292e714d8' target=_blank style='color:#2F92EE;'>#fulvestrant#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7714, encryptionId=8292e714d8, topicName=fulvestrant)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Sun Sep 01 00:46:00 CST 2019, time=2019-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058246, encodeId=4222205824607, content=<a href='/topic/show?id=dafb1e141b8' target=_blank style='color:#2F92EE;'>#Taselisib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17141, encryptionId=dafb1e141b8, topicName=Taselisib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Jun 18 04:46:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345728, encodeId=a50f345e2818, content=了解一下，谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Sep 19 20:48:40 CST 2018, time=2018-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345720, encodeId=bb8a345e20b5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Sep 19 20:33:36 CST 2018, time=2018-09-19, status=1, ipAttribution=)]
    2018-11-02 xiangyuzhou971

    #EST#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2051244, encodeId=ec6220512440e, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Nov 02 05:46:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657071, encodeId=9b08165e07192, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri May 31 18:46:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2065860, encodeId=fd1e2065860e0, content=<a href='/topic/show?id=8292e714d8' target=_blank style='color:#2F92EE;'>#fulvestrant#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7714, encryptionId=8292e714d8, topicName=fulvestrant)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Sun Sep 01 00:46:00 CST 2019, time=2019-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058246, encodeId=4222205824607, content=<a href='/topic/show?id=dafb1e141b8' target=_blank style='color:#2F92EE;'>#Taselisib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17141, encryptionId=dafb1e141b8, topicName=Taselisib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Jun 18 04:46:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345728, encodeId=a50f345e2818, content=了解一下，谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Sep 19 20:48:40 CST 2018, time=2018-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345720, encodeId=bb8a345e20b5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Sep 19 20:33:36 CST 2018, time=2018-09-19, status=1, ipAttribution=)]
    2019-05-31 bsmagic9140

    #TRA#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2051244, encodeId=ec6220512440e, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Nov 02 05:46:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657071, encodeId=9b08165e07192, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri May 31 18:46:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2065860, encodeId=fd1e2065860e0, content=<a href='/topic/show?id=8292e714d8' target=_blank style='color:#2F92EE;'>#fulvestrant#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7714, encryptionId=8292e714d8, topicName=fulvestrant)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Sun Sep 01 00:46:00 CST 2019, time=2019-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058246, encodeId=4222205824607, content=<a href='/topic/show?id=dafb1e141b8' target=_blank style='color:#2F92EE;'>#Taselisib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17141, encryptionId=dafb1e141b8, topicName=Taselisib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Jun 18 04:46:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345728, encodeId=a50f345e2818, content=了解一下，谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Sep 19 20:48:40 CST 2018, time=2018-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345720, encodeId=bb8a345e20b5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Sep 19 20:33:36 CST 2018, time=2018-09-19, status=1, ipAttribution=)]
    2019-09-01 xqptu

    #fulvestrant#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2051244, encodeId=ec6220512440e, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Nov 02 05:46:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657071, encodeId=9b08165e07192, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri May 31 18:46:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2065860, encodeId=fd1e2065860e0, content=<a href='/topic/show?id=8292e714d8' target=_blank style='color:#2F92EE;'>#fulvestrant#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7714, encryptionId=8292e714d8, topicName=fulvestrant)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Sun Sep 01 00:46:00 CST 2019, time=2019-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058246, encodeId=4222205824607, content=<a href='/topic/show?id=dafb1e141b8' target=_blank style='color:#2F92EE;'>#Taselisib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17141, encryptionId=dafb1e141b8, topicName=Taselisib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Jun 18 04:46:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345728, encodeId=a50f345e2818, content=了解一下，谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Sep 19 20:48:40 CST 2018, time=2018-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345720, encodeId=bb8a345e20b5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Sep 19 20:33:36 CST 2018, time=2018-09-19, status=1, ipAttribution=)]
    2019-06-18 qingting

    #Taselisib#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2051244, encodeId=ec6220512440e, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Nov 02 05:46:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657071, encodeId=9b08165e07192, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri May 31 18:46:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2065860, encodeId=fd1e2065860e0, content=<a href='/topic/show?id=8292e714d8' target=_blank style='color:#2F92EE;'>#fulvestrant#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7714, encryptionId=8292e714d8, topicName=fulvestrant)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Sun Sep 01 00:46:00 CST 2019, time=2019-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058246, encodeId=4222205824607, content=<a href='/topic/show?id=dafb1e141b8' target=_blank style='color:#2F92EE;'>#Taselisib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17141, encryptionId=dafb1e141b8, topicName=Taselisib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Jun 18 04:46:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345728, encodeId=a50f345e2818, content=了解一下，谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Sep 19 20:48:40 CST 2018, time=2018-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345720, encodeId=bb8a345e20b5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Sep 19 20:33:36 CST 2018, time=2018-09-19, status=1, ipAttribution=)]
    2018-09-19 天地飞扬

    了解一下，谢谢分享！

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2051244, encodeId=ec6220512440e, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Nov 02 05:46:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657071, encodeId=9b08165e07192, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri May 31 18:46:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2065860, encodeId=fd1e2065860e0, content=<a href='/topic/show?id=8292e714d8' target=_blank style='color:#2F92EE;'>#fulvestrant#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7714, encryptionId=8292e714d8, topicName=fulvestrant)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Sun Sep 01 00:46:00 CST 2019, time=2019-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058246, encodeId=4222205824607, content=<a href='/topic/show?id=dafb1e141b8' target=_blank style='color:#2F92EE;'>#Taselisib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17141, encryptionId=dafb1e141b8, topicName=Taselisib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Jun 18 04:46:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345728, encodeId=a50f345e2818, content=了解一下，谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Sep 19 20:48:40 CST 2018, time=2018-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345720, encodeId=bb8a345e20b5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Sep 19 20:33:36 CST 2018, time=2018-09-19, status=1, ipAttribution=)]
    2018-09-19 医者仁心5538

    学习了

    0

相关威廉亚洲官网

中国晚期乳腺癌维持治疗专家共识

晚期乳腺癌目前难以治愈，但可通过研发新型治疗药物，优化治疗模式等方法来缓解患者的临床症状，改善患者的生活质量，进一步延长患者的生存期。 本文是由中国抗癌协会乳腺癌专业委员会的相关专家共同制定，主要内容包括：乳腺癌维持治疗的概念，药物以及治疗方式的选择。

徐兵河教授：Foundation One®在晚期乳腺癌中的应用

Foundation One®是一种全面基因组测序分析服务，针对所有实体肿瘤（除肉瘤以外）使用组织样本，应用“基于独特靶向富集杂交捕获”的NGS（二代测序）技术，在一次检测中平行提供了315个基因的4种基因变异及TMB和MSI两种基因标签的全面分子信息，更加精准地指导个体化靶向及免疫治疗方案。FoundationOne？的检测结果是经过严谨分析验证的， 同平台下的FoundationOne CDx

徐兵河教授：泛ErbB受体TKI吡咯替尼具有治疗晚期乳腺癌潜力

HER2阳性乳腺癌约占全部患者的20%～30%，HER2阳性也是乳腺癌最重要的独立不良预后因素之一。围绕HER2靶点的新药探索层出不穷，吡咯替尼（HTI-1001）是一种口服、不可逆泛ErbB受体酪氨酸激酶抑制剂（TKI），具有抑制表皮生长因子受体（EGFR）/ HER1，HER2和HER4活性的作用。在Ⅰ期临床研究中，吡咯替尼在HER2阳性晚期乳腺癌和胃癌患者中显示出一定的治疗获益。

[ABC4圆桌会] HER2阳性晚期乳腺癌：以抗HER2为基础，从一线到维持治疗

适才ABC4圆满落下帷幕，徐兵河教授已为读者解读了HER2阳性晚期乳腺癌治疗的新进展；《肿瘤瞭望》邀请了天津肿瘤医院佟仲生教授、中国医科大学附属第一医院滕月娥教授、江苏省肿瘤医院张莉莉和河南省肿瘤医院闫敏教授等梳理和讨论HER2阳性晚期乳腺癌一线到维持治疗内容。

2018 AGO建议：晚期和转移性乳腺癌的诊断和治疗（更新版）

2018年7月，德国妇科肿瘤小组(AGO)发布了晚期和转移性乳腺癌的诊断和治疗建议2018更新版，在过去的16年里，德国妇科肿瘤小组(AGO)乳腺委员会以及发布并更新了早期和转移性乳腺癌的诊断和治疗建议，本文是针对晚期和转移性乳腺癌的诊断和治疗建议的更新，主要内容涉及骨健康和骨转移瘤，乳腺癌的随访，局部复发的管理，内分泌和靶向治疗，化疗，治疗副作用的管理以及支持性下hi了，姑息治疗等。

[ABC4] 勠力同心抵抗疾病，支持晚期乳腺癌患者——访ABC4大奖获得者Musa Mayer女士

第4届国际晚期乳腺癌大奖（ABC4 award）授予来自美国的Musa Mayer女士，以表彰其长期致力于晚期乳腺癌患者的支持工作。《肿瘤来望》在里斯本现场采访了Musa Mayer女士，分享其获奖后感想。